AMT 891
Alternative Names: AMT-891Latest Information Update: 13 Jul 2023
At a glance
- Originator Multitude Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 13 Jul 2023 Discontinued - Preclinical for Multiple myeloma in USA (Parenteral)
- 17 Jun 2022 AMT 891 is available for licensing as of 17 Jun 2022. https://www.multitudetherapeutics.info/partnering
- 17 Jun 2022 Preclinical trials in Multiple myeloma in USA (Parenteral) (Multitude Therapeutics pipeline, June 2022)